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Bradbury, MD, Birmingham, United Kingdom
Objective:To assess the utility of a novel rapid urinary cotinine assay to detect and quantify the level of smoking in patients
with peripheral arterial disease.
Methods: This was a cross-sectional study in a vascular surgical outpatient department of a large teaching hospital.
Participants were 100 consecutive subjects presenting to a hospital outpatient clinic with a diagnosis of intermittent
claudication confirmed by a positive Edinburgh claudication questionnaire and an ankle-brachial pressure index of less
than 0.9. Main outcome measures were patient-offered smoking history, exhaled breath carbon monoxide levels, urinary
cotinine levels as measured by a novel rapid assay, and laboratory-measured creatinine-adjusted urinary cotinine levels.
Results: Fifty-five subjects declared that they were current smokers, 40 declared that they were ex-smokers, and 5 declared
that they were never-smokers. Of the 40 ex-smokers, 6 subjects (15%) had urinary cotinine levels greater than 500 ng/mL
(regular smokers), and a further 2 (5%) had urinary cotinine levels between 100 and 500 ng/mL (light, irregular, or
passive smokers). The rapid urinary cotinine assay had a sensitivity and specificity of 100% and 98%, respectively, in its
ability to detect active smoking, and the degree of smoking correlated well with laboratory creatinine-corrected urinary
cotinine levels (Spearman coefficient, 0.805; P < .001). By contrast, exhaled carbon monoxide had a sensitivity and
specificity of 95% and 89%, respectively, and although it correlated well with urinary cotinine (Spearman coefficient,
0.782; P < .001), it was found on linear regression analysis to be unreliable in differentiating light smokers from
nonsmokers.
Conclusions: Patient-offered smoking history is unreliable because there is no correlation between the patient-reported
number of cigarettes smoked per day and urinary cotinine levels. The novel rapid assay for urinary cotinine described here
is superior to exhaled carbon monoxide measurement in detecting the level of smoking exposure among patients with
intermittent claudication, and its results correlate well with laboratory-measured cotinine. (J Vasc Surg 2005;41:
451-6.)Smoking is by far the single most important risk factor
for peripheral arterial disease (PAD).1-5 Continued smok-
ing is associated with disease progression,6,7 suboptimal
results after vascular and endovascular intervention,8,9 and
a 50% reduction in 5-year mortality after both medical5 and
surgical10 treatment. It is universally recognized that com-
plete and permanent cessation of smoking is by far the most
clinically effective and cost-effective intervention in patients
with PAD (nicotine replacement therapy/buproprion,
£2000 per life-year gained; statins, £13,000 per life-year
gained11). Despite this, the great majority of patients get little
or no evidence-based treatment for their nicotine addiction,
and, as a result, smoking cessation rates remain predictably
and unnecessarily low.3,12 Two major hurdles are establishing
the severity of nicotine addiction at baseline and assessing
compliance with therapy. Patient-offered smoking history is
unreliable,13 routine measurement of plasma or urinary
cotinine (widely held as the gold standard) is impracticable
in the everyday clinical setting, and exhaled carbon mon-
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The aim of this study was to compare a novel rapid assay for
urinary metabolites of nicotine (SmokeScreen; Surescreen
Diagnostics Ltd, Derby, UK) with standard laboratory
measurement of urinary cotinine and exhaled CO in a
hospital vascular outpatient setting.
METHODS
Local ethics committee approval was obtained. One
hundred consecutive patients who had a diagnosis of inter-
mittent claudication and who provided written informed
consent entered the study (Table I). Intermittent claudica-
tion was defined as a positive Edinburgh claudication ques-
tionnaire14 coupled with the finding of an ankle-brachial
pressure index of less than 0.9 in the affected leg. No
patient refused to participate in the study; however, two
patients were excluded from entering the study because
they were unable to satisfactorily complete assessment of
exhaled breath CO because of either an inability to breath-
hold for 20 seconds (n 1) or an inability to blow into the
CO analyzer with a sustained breath (n  1).
Patients were questioned regarding current smoking
status, the number of cigarettes smoked per day, and pack-
years smoked. CO concentrations were measured in an
exhaled breath sample by using Micro CO (Micro Medical,
Rochester, UK). All patients had the breathalyzer test
explained to them in detail and were given the opportunity
to practice. Patients were asked to exhale fully before
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the breath-hold, patients were asked to exhale slowly into
the Micro CO and were encouraged to exhale fully to
sample alveolar air. All participating patients were able to
complete the test to the satisfaction of the clinician. Be-
cause the test has a good reproducibility,15 one CO reading
was deemed sufficient. CO values were expressed in parts
per million (ppm), where 0 to 6 ppm indicates a non-
smoker, 7 to 10 ppm indicates a light smoker, 10 to 20 ppm
indicates a regular smoker, andmore than 20 ppm indicates
a heavy smoker, as recommended by the manufacturer of
the analyzer. A CO level of 7 ppm or more has been
demonstrated to have the greatest sensitivity and specificity
for differentiating between smokers and nonsmokers.15
Urine was collected from patients at the time of their clinic
appointment for SmokeScreen analysis. An aliquot of the
same sample was stored at80°C for later batched labora-
tory analysis. All patients were screened in aMonday morn-
ing clinic between 9:30 AM and noon; thereby, the sampling
times were kept as standardized as possible.
SmokeScreen is a disposable colorimetric assay that
measures all the major urinary metabolites of nicotine,
including cotinine. It is therefore specific to cigarette
smoke and will not be affected by ambient air pollution.
Two milliliters of urine is collected in a syringelike attach-
ment that is added to the reagents in a sealed unit. If
nicotine metabolites are present within the urine, a pink/
orange color change will occur over a 6-minute period. The
degree of color change correlates with the concentration of
nicotine metabolites present. A color chart that takes into
account the concentration of the urine is used to semiquan-
tify smoking habit into none, light, moderate, heavy, and
very heavy. The lower limit of detection is reported to be
60 ng/mL of urinary cotinine, the intra-assay variability is
92.7%, and it has a good interobserver correlation ( 
0.61).16 The SmokeScreen assay was performed with the
Table I. Demographic details, comorbidities, and medica
Variable Never smokers
No. subjects 5
Age, y, median (IQR) 73 (55.5-79)
Sex (M:F) 2:3
Ischemic heart disease
Myocardial infarction/angina 2
Coronary artery bypass graft 0
Cerebrovascular disease
Cerebrovascular accident 0
Transient ischaemic attack 0
Diabetes mellitus 2
Hypertension 3
Medication
Antiplatelet agent 3
Statin 1
Antihypertensive 3
ACE inhibitor 1
IQR, Interquartile range; ACE, angiotensin-converting enzyme.operator blinded to both the patient-reported smokingstatus and the CO result. Urinary cotinine was measured in
an accredited laboratory with a Cotinine Microplate EIA
(Cozart Bioscience Ltd, Abingdon, UK) with a detection
limit for cotinine of 12 ng/mL, and urinary creatinine was
measured by a standard technique on a Roche P800 ana-
lyzer (Roche Diagnostics, Lewes, UK). For the purpose of
this study, creatinine-adjusted urinary cotinine values were
used as the gold standard test for quantifying smoking
status, because the test is noninvasive and allows closer
comparison with the SmokeScreen assay. Because fluid
intake influences the concentration of urinary cotinine and
because urinary creatinine excretion is fairly constant, the
urinary cotinine level was corrected for urinary creatinine
by a previously described regression adjustment.17 Our
standard laboratory reference range indicates that levels less
than 100 ng/mL are consistent with a nonsmoker, and
levels greater than 500 ng/mL indicate a regular smoker.
Cotinine values of 100 to 500 ng/mL indicate a light
regular smoker, an irregular smoking habit, or significant
passive smoking.
RESULTS
Fifty-five subjects declared that they were current
smokers, 40 were ex-smokers, and 5 had never smoked
(Table II). All of the declared smokers had laboratory
urinary cotinine levels consistent with a regular current
smoking habit, and all of the never-smokers had urinary
cotinine levels less than 100 ng/mL (nonsmoking range).
However, of the 40 ex-smokers, 6 subjects (15%) had
urinary cotinine levels greater than 500 ng/mL (regular
smoker), and a further 2 (5%) had urinary cotinine levels
between 100 and 500 ng/mL (light regular smoker, irreg-
ular smoking habit, or significant passive smoking; Fig 1).
Thus, 8 (13%) of 63 active smokers, identified by increased
cotinine levels, denied their smoking habit on direct ques-
tioning. Among smokers, there was no correlation between
agement of patients recruited
Ex-smokers
Current
smokers Total
40 55 100
70 (65.25-77) 65 (60-71) 68 (62.3-74.5)
34:6 35:20 71:29
11 11 24
3 3 6
14
3 4 7
5 2 7
10 4 16
29 34 66
32 42 77
29 35 65
26 28 57
10 11 22l manthe patient-reported cigarettes per day and corrected
s smo
3, he
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Fig 2).
Using laboratory creatinine-adjusted urinary cotinine
values of 100 ng/mL to denote a current smoking habit,
SmokeScreen produced two false-negative tests and no
false-positive tests. This resulted in a sensitivity and speci-
ficity of 100% and 98%, respectively; a positive predictive
value of 0.98; and a negative predictive value of 1. The false
negatives had corrected urinary cotinine values of 155 and
191 ng/mL.With regard to CO in expired breath, a level of
7 ppm or more was used to denote a positive result. Micro
CO produced four false positives (CO [ppm]:corrected
urinary cotinine level [ng/mL]: 7:72, 9:52, 7:34, and
7:11) and three false negatives (CO:corrected urinary coti-
nine level: 3:2950, 4:1212, and 3:191). This resulted in a
sensitivity and specificity of 95% and 89%, respectively, and
a positive predictive value and negative predictive value of
0.94 and 0.92, respectively.
Figs 3 and 4 show the comparison of SmokeScreen
Table II. Subject smoking history and results of near-pati
Declared
smoking habit
No.
subjects Age (y)
Pack
sm
Current smoker 55 65 (60-71) 35 (2
Ex-smoker 40 70 (65.25-77) 32.5 (2
Never-smoker 5 73 (55.5-79) 0 (0
Results represent median (IQR) unless otherwise specified.
CO, Carbon monoxide.
*Pack year  (number of cigarettes smoked per day/20)  number of year
†SmokeScreen results: 0, nonsmoker; 1, light smoker; 2, moderate smoker;
Fig 1. Declared smoking status plotted against correct
500 ng/mL indicates a regular smoker, values between 1
nonsmokers have values less than 100 ng/mL.and exhaled CO measurement against creatinine-ad-justed urinary cotinine in terms of their ability to quan-
tify smoking status in each subject. Both SmokeScreen
(Spearman coefficient, 0.805; P .001) and exhaled CO
(Spearman coefficient, 0.782; P  .001) measurements
correlated well with corrected urinary cotinine results.
To investigate this further, linear regression analysis was
performed by using creatinine-adjusted urinary cotinine
as the dependent variable and by using SmokeScreen
(using nonsmoker as the baseline level) and exhaled CO
(0-6 ppm) as independent variables (Table III). The
regression analysis indicated that exhaled CO at 7 to 10 ppm
cannot reliably distinguish light smokers from nonsmokers
and that SmokeScreen cannot reliably differentiate heavy
smokers from very heavy smokers.
DISCUSSION
Complete and permanent cessation of smoking is by far
the single most clinically effective and cost-effective inter-
vention in patients with PAD, yet it receives little or no
nd laboratory assessment of smoking status
* Exhaled
CO
SmokeScreen
result†
Urinary cotinine/
creatinine ratio
) 20 (15-27) 2.45 (1-4) 2950 (1726-4981)
.25) 4 (3-7) 0.33 (0-4) 16 (12.25-51)
2 (1.5-3.5) 0 (0-0) 16 (12.5-19.5)
ked.
avy smoker; 4, very heavy smoker. Values are expressed as mean (range).
inary cotinine. A corrected urinary cotinine more than
d 500 ng/mL are typical for light or erratic smokers, andent a
-years
oked
2-50
0-52
-0)ed ur
00 anattention in most vascular surgical clinics.3 Exhaled CO
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to provide an accurate assessment of baseline smoking status, the
severity of nicotine addiction, and compliance with therapy. Bi-
omarkermeasurement allows treatment tobe tailored to individ-
ual patient requirements (such as the appropriate dose of nico-
tine-replacement therapy), providesmotivating and re-enforcing
Fig 3. Box plot to show comparison between SmokeS
coefficient, 0.805; P  .001).
Fig 2. Correlation between declared cigarette consum
represents the degree of best fit (R2  0.004).feedback, and improves smoking-cessation rates.16,18-20 Thisstudy confirms that patient-offered smoking history is un-
reliable both in terms of smoking status and, in admitted
smokers, the level of smoking (nicotine addiction), because
there was no correlation between the patient-reported
number of cigarettes smoked per day and urinary cotinine
levels. In part, this lack of correlation could be due to
and corrected urinary cotinine (Spearman correlation
of smokers and corrected urinary cotinine. The linecreenptionunderreporting by the subject, because many subjects deny
 .0
or exh
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that because of wide variations in the number of puffs taken
per cigarette and in the depth of each inhalation, the
number of cigarettes smoked is a poor surrogate marker of
consumption. In this study, 13% of current smokers (as
detected by urinary cotinine) denied that they were cur-
rently smoking. Although confronting patients with this
information requires care, biomarker feedback, properly
used, can help patients to discuss their nicotine addiction
more openly, thus helping them to seek and obtain appro-
priate treatment.
Measurement of exhaled CO is quick and easy to
perform in the clinical setting and had a sensitivity and
specificity of 95% and 89%, respectively, for correctly iden-
Fig 4. Box plot to show comparison between exhaled b
An expired CO of 0 to 6 ppm represents a nonsmoker, 7
heavy smoker (Spearman correlation coefficient, .782; P
Table III. Linear regression analysis of the relationship be
urinary cotinine
Variable Coefficient
SmokeScreen* result
Light 2160.4 5
Moderate 3144.1 3
Heavy 3866.7 4
Very heavy 3651.4 5
Exhaled CO (ppm)
7-10 913 5
11-20 3038 3
20 3666 3
CO, Carbon monoxide.
*For SmokeScreen, the nonsmoker category was used as the baseline, and ftifying current smokers. All four false positives had levels inthe light-smoker range (7-10 ppm) that could be explained
by passive smoking, exposure to pollution, or an underlying
inflammatory lung condition (eg, asthma or chronic ob-
structive airway disease).21 Nevertheless, on the basis of
CO alone, these four patients would have been falsely
“accused” of being smokers, possibly leading to a loss of
trust between the patient and doctor. The three false neg-
atives are probably explained by the short (approximately
4 hours) half-life of CO, becauseMicro COwill detect only
smoking within the previous 12 hours. This limits the
utility of CO in the assessment of light or erratic smokers,
especially if it is used early in the morning before a cigarette
has been smoked. Thus, although, in this study, there
seems to be a strong correlation between CO and adjusted
carbon monoxide (CO) and corrected urinary cotinine.
a light smoker, 11 to 20 a smoker, and more than 20 a
01).
n SmokeScreen/exhaled carbon monoxide and corrected
t P value R2
0.567
4.10 .001
8.16 .001
9.14 .001
6.65 .001
0.537
1.74 .086
7.64 .001
9.52 .001
aled CO, 0 to 6 ppm was used as the baseline.reath
to 10twee
SE
26.5
85.4
23.3
49.3
26.5
97.9
85.1urinary cotinine, the linear regression model clearly indi-
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smokers from nonsmokers.
Cotinine, the primary metabolite of nicotine, can be
detected in serum, saliva, and urine; has a long half-life
(approximately 16 hours); fluctuates much less than CO on
a day-to-day basis; and can quantify smoking habit over the
preceding 3 to 4 days.22 Despite these obvious advantages,
urinary cotinine measurement is rarely undertaken in clin-
ical practice because the laboratory assay is time consuming
and expensive, and delay occurs because testing must often
be batched. The resulting delay clearly reduces the effect
that testing can have on the consultation and treatment and
limits is use predominantly to that of a research tool.
In this study, urinary cotinine testing with Smoke-
Screen was clearly superior to exhaled CO and correlated
well with laboratory-measured corrected urinary cotinine.
In particular, SmokeScreen could distinguish between light
smokers and nonsmokers, and this is important because
there is no safe level of smoking. SmokeScreen is, therefore,
a useful addition to the clinician’s armamentarium. It will
facilitate the optimization of smoking-cessation rates, thus
improving the natural history of PAD and the results of
medical, vascular, and endovascular therapies.
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